MA1-410

antibody from Invitrogen Antibodies

Targeting: PGR NR3C3, PR

Provider product page for MA1-410

Western blot

Immunoprecipitation

Immunohistochemistry

Chromatin Immunoprecipitation

Other assay

Antibody data

Antibody Data
Antigen structure
References [61]
Comments [0]
Validations
Western blot [1]
Immunohistochemistry [1]
Other assay [13]

Submit

Product number: MA1-410 - Provider product page
Provider: Invitrogen Antibodies
Product name: Progesterone Receptor Monoclonal Antibody (PR-AT 4.14)
Antibody type: Monoclonal
Antigen: Synthetic peptide
Reactivity: Human, Mouse, Rat, Bovine, Rabbit
Host: Mouse
Isotype: IgG
Antibody clone number: PR-AT 4.14
Vial size: 100 µg
Concentration: 1 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

PGR protein structure - MA1-410 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Scoring results PRB experiment 1 . Results from manual scoring of PRB immunohistochemistry results in stroma (upper panel), luminal epithelium (LE, middle panel) and myometrium (bottom panel). The ""box-and-whisker plot"" represents the median value with 50% of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. An asterisk indicates a significant (p < 0.05) difference compared to the OvxC group.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Immunohistochemistry experiment 1 . Representative images of immunohistochemical results from each hormone treatment group in experiment 1, PRAB A-H , PRB I-O . Treatment groups are as follows: OvxC: A and I , 24E: B and J . 24P: C and K , 48E: D and L , 48P: E and M , 24E+24P: F and N , 24P+24E: G and O . Magnification bar 30 mum in images A-H and 50 mum in images I-O.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Immunohistochemistry experiment 2 . Representative images of immunohistochemical results from the immature ( A ), cycling ( B,C ) and pregnant rats ( D-H ). Image F shows PRB immunostaining while all the others show PRAB. The arrow in image H indicates the negative cells in the placenta. Magnification bar 30 mum in all images.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Immunohistochemistry experiment 3 . Representative images of immunohistochemical results from the agonist treated rats, PRAB in left columnand PRB in right column. Representative images are shown from a rat in each treatment group as follows: OvxC ( A,B ), E2 ( C,D ), PPT ( E,F ) and DPN ( G,H ). The insert shows the myometrium from the same uterus. Magnification bar 30 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Progesterone receptor protein expression in guinea pig uteri during late gestation. A , immunoblot picture showing progesterone receptor A and B (PRA and PRB) and GAPDH loading control bands in one representative uterine sample of the gestational stage groups 45d, 55dA, 55dB and 62d. Duplicates of 50 ug (left) and 100 ug (right) protein content were run from each uterine extract. B , PRA and PRB protein relative abundance in the gestational stage groups from 45d pregnancy to Labor. *, PRA significantly different from 67d and Labor; #, PRA significantly different from 67d; + , PRB significantly different from Labor; p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Progesterone Receptor expression in mesenchymal cells in the intestine, not in the epithelium. A-E) PR immunohistochemistry on the mouse colon (A) and small intestine (B,C) where rare cells express PR (arrowhead). And in an adenoma of an Apc Min/+ mouse (D). PR is widely expressed in the mouse uterus (E). F,G) In situ hybridization in mouse uterus (F) and small intestine (G). All murine tissue shown was taken from A female animal in diestrous stage, when progesterone is high [39] . H-J) PR Expression in the human colon is located in mesenchymal cells (I) and the smooth muscle layer (J), similar to the mouse intestine. For in situ hybridization, thick (10 um) sections were used, which makes identification of mesenchymal cells difficult. K) PR immunoblot on the mouse colon and small intestine. L) PR immunoblot on a panel of colon cancer cell lines shows no expression of either PR-A or PR-B isoform. The breast cancer cell line T47D is used as a positive control.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Evaluation of androgen and vitamin D receptor agonists response in BC lines: a Western blot analysis of 15 breast cancer cell lines for ER, AR, VDR, PR, and Her2 expression. Two AR+ and two AR- prostate cancer cell lines, LNCaP, LAPC-4, PC-3, and DU-145, respectively, were used as controls for AR expression. 30 ug extract was loaded in each lane of a 4-12 % 20-well SDS-PAGE gel, which was transferred onto a nitrocellulose membrane and probed with the following antibodies: ERalpha (1:750, Santa Cruz sc-8002), progesterone receptor (1:1000, Thermofisher Scientific MA1-410), HER2 (1:2000, Abcam ab2428), androgen receptor (N-20) (1:1000, Abcam sc-816), vitamin D receptor (1:1000, Thermofisher Scientific MA5-14617). beta-Actin is used as a loading control (1:5000, Sigma A2228). The results of VDR and AR agonist treatment experiments in panels b and c are plotted as percent viability of the cells in comparison to the vehicle control. Error bars represent mean +- standard error of mean (SEM). These experiments were repeated at least three times. The statistical significance of the drug treatments was determined using two-tailed Student's T -test. * P < 0.05, ** P < 0.01. Cal calcitriol, DHT dihydrotestosterone. b VDR agonist calcitriol treatment on cancer cell lines: breast cancer cell lines [ black VDR(+) and hatched VDR(- or low)] were plated in their respective media with complete serum in triplicates. 24-48 h after plating, the cells were treated with 100 nM calcitriol fo

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 mRNA and protein expression of PRs ( A , C ) and ERalpha ( B , D ) in uterine tissues (endometrium and myometrium) on 4th and 13th day of estrous cycle, in pregnancy and anestrus phase. Data were normalized against beta-actin (ACTB) for proteins expression and against GAPDH for mRNA expression. Each bar represents one experimental group with SEM. Statistical differences were analyzed by two-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test using GraphPad PRISM (Version 8.3.0). The lowest statistical significance was P < 0.05. Asterisks indicate statistical differences between endometrium and myometrium (* P < 0.1; *** P < 0.001; **** P < 0.0001). Different letters indicate statistical differences ( P < 0.05) between the experimental groups throughout endometrium (A, B) and myometrium (a-c) respectively.